Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 2;12(6):1373.
doi: 10.3390/diagnostics12061373.

Inflammatory and Cardiac Biomarkers in Relation with Post-Acute COVID-19 and Mortality: What We Know after Successive Pandemic Waves

Catalina Lionte  1   2 , Victorita Sorodoc  1   2 , Raluca Ecaterina Haliga  1   2 , Cristina Bologa  1   2 , Alexandr Ceasovschih  1   2 , Ovidiu Rusalim Petris  2   3 , Adorata Elena Coman  2   4 , Alexandra Stoica  1   2 , Oana Sirbu  1   2 , Gabriela Puha  1   2 , Mihai Constantin  1   2 , Gabriela Dumitrescu  1   2 , Victoria Gorciac  2   5 , Andrei-Costin Chelariu  2   6 , Andreea Nicoleta Catana  7 , Elisabeta Jaba  8 , Laurentiu Sorodoc  1   2
Affiliations

Inflammatory and Cardiac Biomarkers in Relation with Post-Acute COVID-19 and Mortality: What We Know after Successive Pandemic Waves

Catalina Lionte et al. Diagnostics (Basel). .

Abstract

Background: Biomarkers were correlated with mortality in critically ill COVID-19 patients. No prediction tools exist for noncritically ill COVID-19 patients. We aimed to compare the independent prognostic value of inflammation and cardiac biomarkers for post-acute COVID-19 patients and the 30-day mortality rate in noncritically ill COVID-19 patients, as well as the relation with the virus variant involved.

Methods: This observational cohort study was conducted at an emergency clinical hospital between 1 October 2020 and 31 December 2021. We included consecutive patients with biomarkers determined within 24 h of presentation, followed up at least 30 days postdischarge.

Results: Post-acute COVID-19 was diagnosed in 20.3% of the cases and the all-cause 30-day mortality rate was 35.1% among 978 patients infected with variants of concern. Neutrophil-to-lymphocyte ratio (1.06 [95%CI, 1.01-1.11], p = 0.015) and NT-pro BNP were correlated with 30-daymortality, while the monocyte-to-lymphocyte ratio (2.77 [95%CI, 1.10-6.94], p = 0.03) and NT-pro BNP (1.68 [95%CI, 1.00-2.84], p = 0.05) were correlated with post-acute COVID-19. High-sensitivity to troponin was associated with 30-day mortality (1.55 [95%CI, 1.00-2.42], p = 0.05). A Cox proportional-hazards model confirmed that NT-pro BNP was independently associated with mortality. NT-pro BNP remained independently associated with 30-day mortality during follow-up (1.29 [95%CI, 1.07-1.56], p = 0.007) after adjustment for confounders.

Conclusion: Inflammation and cardiac biomarkers, determined upon admission and predischarge, in a cohort of hospitalized noncritically ill COVID-19 patients throughout successive pandemic waves, showed a predictive value for post-acute COVID-19 and 30-day mortality.

Keywords: 30-day mortality; NT-pro BNP; high sensitivity cardiac troponin; inflammatory biomarkers; post-acute COVID-19; variants of concern.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Post-acute COVID-19 in the cohort analyzed.
Figure 2
Figure 2
(a) Box plot demonstrating the logarithmic concentrations of NT-pro BNP in relation with 30-day mortality; °, represent outliers; (b) Cox proportional-hazards model assessing the relationship between NT-pro BNP groups and survival during follow-up.
Figure 3
Figure 3
Kaplan–Meier survival curves regarding all-cause 30-day mortality according with NT-pro BNP groups in the whole study population.
Figure 4
Figure 4
Boxplot demonstrating the logarithmic concentrations of predischarge high-sensitivity troponin I (hs-TnI) among the main outcome groups after 30 days follow up; °, represent outliers; *, represent extreme values.
See this image and copyright information in PMC

References

    1. Butt A.A., Dargham S.R., Chemaitelly H., Al Khal A., Tang P., Hasan M.R., Coyle P.V., Thomas A.G., Borham A.M., Concepcion E.G., et al. Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar. JAMA Int. Med. 2022;182:197–205. doi: 10.1001/jamainternmed.2021.7949. - DOI - PMC - PubMed
    1. Michelen M., Manoharan L., Elkheir N., Cheng V., Dagens A., Hastie C., O’Hara M., Suett J., Dahmash D., Bugaeva P., et al. Characterising long COVID: A living systematic review. BMJ Glob. Health. 2021;6:e005427. doi: 10.1136/bmjgh-2021-005427. - DOI - PMC - PubMed
    1. Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601–615. doi: 10.1038/s41591-021-01283-z. - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention Post-COVID Conditions. [(accessed on 5 January 2022)]; Available online: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.
    1. Anka A.U., Tahir M.I., Abubakar S.D., Alsabbagh M., Zian Z., Hamedifar H., Sabzevari A., Azizi G. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management. Scand. J. Immunol. 2021;93:e12998. doi: 10.1111/sji.12998. - DOI - PMC - PubMed